PubMed=2535691
Ciccarone V.C., Spengler B.A., Meyers M.B., Biedler J.L., Ross R.A.
Phenotypic diversification in human neuroblastoma cells: expression of distinct neural crest lineages.
Cancer Res. 49:219-225(1989)

PubMed=10485488
Glick R.D., Swendeman S.L., Coffey D.C., Rifkind R.A., Marks P.A., Richon V.M., La Quaglia M.P.
Hybrid polar histone deacetylase inhibitor induces apoptosis and CD95/CD95 ligand expression in human neuroblastoma.
Cancer Res. 59:4392-4399(1999)

PubMed=15720811; DOI=10.1593/neo.04310
Walton J.D., Kattan D.R., Thomas S.K., Spengler B.A., Guo H.-F., Biedler J.L., Cheung N.-K.V., Ross R.A.
Characteristics of stem cells from human neuroblastoma cell lines and in tumors.
Neoplasia 6:838-845(2004)

PubMed=15892104; DOI=10.1002/gcc.20198
Mosse Y.P., Greshock J., Margolin A.A., Naylor T., Cole K., Khazi D., Hii G., Winter C., Shahzad S., Asziz M.U., Biegel J.A., Weber B.L., Maris J.M.
High-resolution detection and mapping of genomic DNA alterations in neuroblastoma.
Genes Chromosomes Cancer 43:390-403(2005)

PubMed=17506115; DOI=10.1002/nbm.1181
Peet A.C., McConville C.M., Wilson M.P., Levine B.A., Reed M., Dyer S.A., Edwards E.C., Strachan M.C., McMullan D.J., Wilkes T.M., Grundy R.G.
1H MRS identifies specific metabolite profiles associated with MYCN-amplified and non-amplified tumour subtypes of neuroblastoma cell lines.
NMR Biomed. 20:692-700(2007)

PubMed=25877200; DOI=10.1038/nature14397
Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.
A resource for cell line authentication, annotation and quality control.
Nature 520:307-311(2015)

PubMed=26342562; DOI=10.1016/j.scr.2015.08.008
Ross R.A., Walton J.D., Han D., Guo H.-F., Cheung N.-K.V.
A distinct gene expression signature characterizes human neuroblastoma cancer stem cells.
Stem Cell Res. 15:419-426(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=30971826; DOI=10.1038/s41586-019-1103-9
Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M., Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R., Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P., van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L., Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.
Nature 568:511-516(2019)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)